MNPR

NASDAQ Healthcare

Monopar Therapeutics Inc. - Common Stock

Biotechnology

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

๐Ÿ“Š Market Data
Price$108.52
Volume192,891
Market Cap726.98M
Beta1.480
RSI (14-Day)73.8 Overbought
200-Day MA$70.13
50-Day MA$73.85
52-Week High$112.57
52-Week Low$29.18
Forward P/E-34.59
Price / Book5.27
๐ŸŽฏ Investment Strategy Scores

MNPR scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 14/100โ–ผ -1
High dividend yield + low volatility
๐Ÿš€ Moon Shot 62/100โ–ฒ +8
High growth potential (high beta + oversold)
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 88/100โ–ผ -8
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐ŸŽˆ Over-Hyped (88/100) โ€” this strategy Overbought stocks (potential short candidates).

Lowest fit among scored strategies: ๐Ÿ”ช Falling Knife (1/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find MNPR in your text

Paste any article, transcript, or post โ€” the tool will extract MNPR and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.